Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized, Controlled Phase 2a/b Study of PEG-rIL-29 in Chronic Hepatitis C
2009-011786-80Phase 2Completed
- Sponsor
- ZymoGenetics
- Start
- Nov 2009
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial of peginterferon lambda-1a in chronic hepatitis C (CHC) (3 arms), sponsored by ZymoGenetics. Primary endpoints: Phase 2a Part 1 safety and tolerability, Phase 2a Part 1 antiviral activity and 1 more. Started Nov 2009; status: completed.
02
Drugs
peginterferon lambda-1a
03
Conditions
chronic hepatitis C (CHC)
Beyond the preview
Go deeper on 2009-011786-80.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-011786-80.